

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

APPLICANT:

Garth Powis

TITLE:

USES OF THIOREDOXIN

SERIAL NO.

10/600,957

ATTORNEY REF:

126387.530

DATE OF DEPOSIT:

January 5, 2004

I HEREBY CERTIFY THAT THIS INFORMATION DISCLOSURE STATEMENT TOGETHER WITH THE DOCUMENTS CITED THEREIN IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, MAIL STOP DD, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Jennifer Martinez

(Typed or printed name of person mailing paper or fee)

Documents Enclosed:

- 1. Information Disclosure Statement with cited references;
- 2. Certificate of Mailing;
- 3. Postcard

Attorney Docket No.: 126387.530 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

VIS, Garth

Serial No.

10/600,957

Group Art Unit: 1642

Filed:

June 20, 2003

Examiner: Not yet assigned

For:

USES OF THIOREDOXIN

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Copies are provided. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.



AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to deposit account no. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Raymond a Nucler

Raymond A. Miller Registration No. 42,891

Pepper Hamilton LLP One Mellon Bank Center 50th Floor 500 Grant Street Pittsburgh, PA 15219

Telephone: (412) 454-5813 Facsimile: (412) 281-0717 Date: January 5, 2004

.

Substitute								Complete i	f Known		_
INFORMATION DISCLOSURE STATEMENT BY APPLICANT							Application N	lumber	10/600,957		
							Filing Date		June 20, 2003		
							First Named Inventor		POWIS, Garth		_
							Group Art Unit		1642		_
(use as many sheets as necessary)							Examiner Nan		Not yet assigned		_
Sheet	1	of 2					Attorney Docket Number		126387.530		_
Bilect			1 01			I CO ID A OPTERATOR	· · · · · · · · · · · · · · · · · · ·	ict (valido)	120307.330		_
Examiner's	Cite U.S. Patent Document					J.S. PATENT DOCUMENTS Name of Patentee or Applicant of		Date of	Pages, Columns, Lines, Wh		he
Initials	No.	Number Kind Code (if known)					Document	Publication of	Relevant Passages or Releva Figures Appear		
						1		Cited Document MM-DD-YYYY			
					wn)						
			223980			Powis		12-04-2003			
	l	20020	055131		EOD	Powis	NO DOCTIMEN	05-09-2002	L ,	<u> </u>	
Examiner's	Cite	Fore	eign Daten	Docume			NT DOCUMEN tee or Applicant of	Date of	Pages, Colum	nc Lines	Т
Initials	No.	Foreign Patent Document			111	Cited Document		Publication of	Where Relevan	nt Passages	١
		Office	Number	Kind C	ode	1		Cited Document	or Relevant Fig	ures Appear	
				(if kno	wn)			MM-DD-YYYY			
		PCT	US97-	22292		POWIS	·, ·· · · · ·				T
		wo	91 043	20		Aktibolaget,	Astra	4/4/1991			T
								inent Pages, Etc.			
Examiner's Initials	Cite No.	magazir						when appropriate), tit e-issue number(s), pul			
		Baker, A	A., et al: '	Thioredo	xin, a g	gene found overex	pressed in human car	ncer"Cancer Research	57(22):5162-516	7 (1997)	t
		Powis, G., et al.: "Selenium and the Thioredoxin Redox System" Oncology Research 9(6-7):303-312 (1997)									T
***								proliferation and a do			T
	 	Berggre	oxin revers	es the tran	sforme	ed phenotype of h	uman breast cancer co	ells" Cancer Research ession in Human Tun	1 56(24):5/65-5// nors and Cell Line	0 (1996) ·s"	+
						XP002062159 (No		ossion in riaman ran			
		Gasdaska, J.R., et al.: Cell Growth Differentiation (December 1995)									Ι
		Tockman,et al.: Cancer Research (Suppl) 52: 2715-2718 (1992)									Ι
		Oblong, J.E.: Cancer Chemoth Pharmacol, 34:434-438 (1994)									Ι
		Gura: Science 278:1041-1042 (1997)									Γ
		Jain: Sci. Am, 271:58-65 (1994)									T
		Gasdaska, J.R.: Biochem Pharmacol; 52:1741-1747 (1996)									Ţ
		Hartwell, et al: Science: 278:1064-1068 (1997)									I
		Kirkpatrick, D.L., "Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides" Biochemical Pharmacology: 55: 987-996 (1998)									
		Kirkpatrick, D. L., et al., "Stimulation of Apoptsis by a Redox Active Disulfide" Proc. Am. Assocation, Cancer Res. 36 (1995): 2541									Ī
	 	Drexler, et al. Leukemia and Lymphoma, 9:1-25 (1993)									t
						:181-207 (1984)				<u> </u>	†
		1				y/Hematology, 14	:29-39 (1993)		·····		t
	 	Mustafa O., et al.: International Journal of Oncology, 8(5):883-888 (1996)									†
	-	Freshne	y: Culture	of Anima	l Cells	, a Manual of Bas	ic Technique, Alan R	. Liss, Inc., Pg. 4 (19	83)		†
-111	L	I	-			. C'11' N					_1

Mau, B.L., et al.: Biochem. Pharmacol., 43: 1613-1620 (1992)

Powis, G., et al.: Thioredoxin Redox Signalling: a Novel Target for Anti-Cancer Drug Development, Anti-Cancer Drugs,

7:121-126 (1996)

		Complete if Known					
Substitute for	or form 1449/PTO	Application Number	10/600,957 June 20, 2003 POWIS, Garth 1642 Not yet assigned				
	INFORMATION DISCLOSURE	Filing Date					
	STATEMENT BY APPLICANT	First Named Inventor					
	(use as many sheets as necessary)	Group Art Unit					
	(use as many sneets as necessary)	Examiner Name					
	Attorney Docket Number		126387.530				
	Schallreuter, K.U., Biochem Biophys Acta, 1:	504: 14-20 (1990)					
	Powis, et al., Oncology Research, 6 (10-11):539-44 Gadaska, P.Y., et al.: Biochem Biophys ACTA 1218:292-296 (1994)						
Examiner Signature		Date Considered					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.